The θ-cap operating principle — and whether it is physically buildable

If a theta-cap is to supply the wiring-axis function at all, the dynamics force one mode: minimum-effective amplitude, matched to the individual wiring deficit, applied continuously, since nothing is banked. Physically every component (theta-tACS, closed-loop phase-locking, multi-electrode long-range montages) exists, but the assembly does not, and feasibility is not benefit. efficacy=0.

Putting the four experiments of §20 and the population picture of §23 together pins the operating point on all sides: drive at the minimum amplitude that produces a real routing change, matched to the individual wiring deficit, and do so continuously. Weaker is inert, stronger over-synchronises, intermittent reverts, and nothing is banked because the substrate has no plasticity. The cap is a wearable drug with no half-life past removal. This chapter states that forced operating principle, grades the one open variable (duty cycle), and then asks the engineering question the user posed directly: is such a device physically realisable today? Feasibility of the apparatus is graded [O], and is not evidence of benefit — efficacy = 0.

The drug principle: effect present only during exposure

The cap restores the wiring-axis coordination only while it is on, with no carryover, no consolidation, and no acquired dependence (§20). The pharmacokinetic analogy is not a metaphor here: the cap is an additive drive term and the substrate carries no state variable that persists past the drive, so the moment the drive stops the deficit dynamics resume in full. That is exactly a drug’s kinetics — effect present only during exposure, zero residual after clearance. A pacemaker is a drug you wear instead of swallow.

Minimum-effective is two-sided, and the amplitude must be matched

“Minimum effective” is a real constraint pinned on both sides, not a slogan for “as weak as possible.” Below the window the cap does nothing: only the coherence-forcing external clock routes, only inside inj ≈ 0.08–0.10, and a drive that produces no routing change is not gentle — it is absent. Above the window the cap over-synchronises: the over-sync fraction rises monotonically with amplitude and is minimised at the window (§23). And a fixed amplitude is itself wrong — a single window value over-syncs the milder-deficit cases — so the amplitude must be matched to the individual wiring deficit, the smallest value inside that person’s routing window. The safe band is narrow and deficit-specific.

Therefore: minimum-effective, matched, continuous — and why it is the only mode

Every alternative is closed. Chemistry cannot do it: no chemical reaches the wiring axis (§19); the cap-type θ-supply is the only handle on W. There is no permanent repair in the model: the substrate has no plasticity, so the benefit cannot be banked and must be continuously supplied. Over and under both fail: weaker is inert, stronger over-syncs — there is no safe high dose and no set-it-low-and-forget-it. Intermittent reverts: a gap in dosing is a gap in function. So the mode is forced — the minimum effective, deficit-matched amplitude, applied continuously — and it is also the molecularly safe operating point, since the sub-fold carrier accumulates no irreversible fatigue and the gentlest amplitude is also the lowest thermal cost (§20).

The one open variable: duty cycle and plasticity [O]

The principle fixes the amplitude and the necessity of ongoing dosing unconditionally. It leaves one variable open, and honesty requires grading it [O] rather than asserting it: must dosing be strictly continuous, or could it relax to periodic re-dosing? This model answers strictly continuous — because it has no plasticity. But the real-world rationale for low-intensity stimulation is precisely that its effects can outlast the stimulation through synaptic plasticity. If gentle, correctly-phased pacing induced lasting potentiation of the broken long-range edges, the duty cycle could relax to periodic re-dosing as that after-effect decays. Three qualifications keep this firmly open: this model cannot show it (no plasticity variable, by construction); reported after-effects decay over tens of minutes to a couple of hours, not permanently; and even at its best the drug principle still holds — the effect must be re-supplied, only the interval is open. Crucially, the sign of any such plasticity is set by the cap’s phase: in-phase coupling potentiates a connection, anti-phase depotentiates it — so a plasticity-aware cap could in principle repair or further damage the wiring depending on phase. That is a reason for caution, not optimism.

Is it physically buildable? A feasibility review [O]

The user asked the engineering question plainly: granting the model, is such a device realisable now? The honest answer is that every component the operating principle demands exists today in research form, but the specific assembly does not — and feasibility of the apparatus says nothing about benefit. Take the demands one by one. A θ-band oscillatory drive is transcranial alternating current stimulation (tACS) in the theta band, a low-intensity sinusoidal current that entrains oscillations — routine. A structured, forced carrier (the model’s decisive requirement, since passive lanes are inert) is closed-loop, phase-locked EEG-tACS, which tracks the instantaneous phase of the ongoing rhythm and drives in-phase — demonstrated, including the in-phase / anti-phase contrast. A drive that targets long-range coordination rather than one spot is multi-electrode, phase-shifted tACS, developed specifically to alter between-area connectivity, where in-phase stimulation increases coordination and anti-phase disorganises it — the same sign rule the plasticity caution above turns on; such montages have even produced a moving “travelling-wave” field, echoing the paper’s own §13 result. Individualised targeting is standard practice: subject-specific MRI-optimised montages, an individual carrier frequency, and intensities kept below the sensation threshold. And continuous, wearable delivery exists as cap-style home tACS systems, tele-supervised, with per-electrode currents held below conventional safety limits.

So the parts are real. What is not real is the combination the principle requires all at once: individualised and phase-structured and amplitude-windowed and network-targeted on the broken long-range edges specifically and continuous. Four obstacles keep this [O]. (1) No deficit readout. The principle demands an amplitude matched to the individual wiring deficit, but there is no validated in-vivo measure of “that person’s wiring deficit” to set the window — the matching target is currently unmeasurable. (2) The narrow window is a real risk. The same dynamics that make the cap work make over-shooting it over-synchronise the network — the seizure analogue — so an un-titrated or open-loop device is not merely ineffective but potentially harmful. (3) Spatial targeting of the broken edges at depth and across distributed long-range pathways is at the edge of what scalp montages (and emerging temporal-interference methods) can do. (4) The plasticity sign problem: if after-effects exist, the wrong phase depotentiates rather than potentiates — the device could entrench the deficit. Above all, the model assigns efficacy = 0: that the drive is buildable is a statement about hardware, not about whether wearing it helps anyone. Every fraction and coupling value here is an in-silico coupling state, not a clinical response rate or a dose; efficacy = 0 throughout. This is a mechanism-level result about the fault structure of autism as represented in the VP framework — not medical advice, a diagnosis, a treatment protocol, or a cure.